Cargando…
Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin-resistant cell line to oxaliplatin by inhibiting excision repair cross-complementing group 1 protein expression
Oxaliplatin (Oxa)-based chemotherapy is widely used as the first-line treatment for colorectal cancer (CRC). However, Oxa-resistance is common for many postoperative CRC patients. To explore drug resistance in CRC, an Oxa-resistant cell line, HCT116/Oxa, was established from parental HCT116 cells. T...
Autores principales: | Li, Ji-Min, Jiang, Guan-Min, Zhao, Liang, Yang, Fang, Yuan, Wei-Qi, Wang, Hao, Luo, Yi-Qin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775812/ https://www.ncbi.nlm.nih.gov/pubmed/31436301 http://dx.doi.org/10.3892/or.2019.7291 |
Ejemplares similares
-
Gene Structure Evolution of the Short-Chain Dehydrogenase/Reductase (SDR) Family
por: Gabrielli, Franco, et al.
Publicado: (2022) -
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin
por: Rao, Devika, et al.
Publicado: (2019) -
PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway
por: Li, Huafu, et al.
Publicado: (2021) -
Medium- and short-chain dehydrogenase/reductase gene and protein families: MDR and SDR gene and protein superfamilies
por: Jörnvall, H.
Publicado: (2008) -
Genome-Wide Identification and Characterization of Short-Chain Dehydrogenase/Reductase (SDR) Gene Family in Medicago truncatula
por: Yu, Shuhan, et al.
Publicado: (2021)